Daré Bioscience, Inc. (DARE) Stock Analysis — Probabli.AI
AI-powered analysis for DARE (Daré Bioscience, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $3.26 · Market cap: $45.1M · AI consensus: Bullish
Daré Bioscience Inc. is a small-cap biotech with a strong focus in women's health therapeutics. The company has shown recent success, including the FDA fast track designation for DARE-BV and positive Phase 3 trials, which significantly boost its outlook. Although fundamental challenges exist, such as a reliance on future funding and commercialization hurdles, the stock's upside potential remains…
Probabilistic 1-Year Outlook
- Bull 5000% · Neutral 3000% · Bear 2000%
- Daré Bioscience's recent FDA fast track designation and positive phase 3 trial results suggest a significant upward momentum in the short term. However, the company's small revenue base and reliance on future milestones…
5-Year Outlook
- Bull 6000% · Neutral 2500% · Bear 1500%
SWOT Highlights
- Strength: FDA fast track designation for DARE-BV.
- Strength: Strong analyst consensus with mean target price significantly above current valuation.
- Risk: Very small revenue base relative to valuation.
- Risk: Dependence on capital markets for funding pipeline activities.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
2 Wall Street analysts rate DARE a STRONG BUY with a mean price target of $10.
Analysis generated May 4, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/DARE.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.